Single agent and combination chemotherapy of non-Hodgkin's lymphomas are reviewed. Cyclophosphamide, vincristine and adriamycin appear to be the most effective single agents. Bleomycin is also effective and particularly indicated either in combination or in patients with active disease and concomitant myelosuppression. Corticosteroids are mostly active in lymphocytic lymphoma. Nitrosourea derivatives appear to be only moderately effective compared to other agents. There are a number of active combinations presently on study, but none can yet be recognized as the treatment of choice for all histologic types. Available data show that cyclic combination chemotherapy produces a higher percentage of complete remissions compared to single agents. This also applies to median duration of response and median survival time. Treatment of non-Hodgkin's lymphomas has improved during the past few years primarily because of intensive cyclic combination chemotherapy and new effective agents. There is a need for an entirely new approach which should be based on standardized histopathologic and staging classification as well as on controlled studies.
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging